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a  b  s  t  r  a  c  t
In acute  myeloid  leukemia  (AML),  refractory  disease  is  a major  challenge  and  the  leukemia  microenvi-
ronment  may  harbor  refractory  disease.  Human  AML  cell  lines  KG-1  and  HL-60  expressed  receptors  also
found  on endothelial  cells  (ECs)  such  as  VEGFRs,  PDGFRs,  and  cKit.  When  human  AML  cells  were  co-
cultured  with  human  umbilical  vein  endothelial  cells  (HUVECs)  and  primary  bone  marrow  endothelial
cell  (BMECs),  the AML  cells  were  more  resistant  to cytarabine  chemotherapy,  even  in transwell  co-culture
suggesting  angiocrine  regulation.  Primary  BMECs  secreted  signiﬁcantly  increased  levels of VEGF-A  and
PDGF-AB  after  exposure  to cytarabine.  Pazopanib,  a receptor  tyrosine  kinase  inhibitor  (RTKI)  of  VEGFRs,
PDGFRs,  and  cKit, removed  EC protection  of  AML  cells  and  enhanced  AML  cell sensitivity  to  cytarabine.
Xenograft  modeling  showed  signiﬁcant  regression  of  AML  cells  and abrogation  of  BM  hypervascularity  in
RTKI treated  cohorts.  Together,  these  results  show  direct  cytotoxicity  of  RTKIs  on  AML cells  and  reversal
of  EC  protection.  Combining  RTKIs  with  chemotherapy  may  serve  as promising  therapeutic  strategy  for
patients  with  AML.
ublis©  2015  The  Authors.  P
. Introduction
Although a majority of patients with acute myeloid leukemia
AML) achieve initial remission after standard induction
hemotherapy, refractory disease remains a major challenge,
specially in older individuals [1,2]. Treatment resistance may
e due to leukemia cell-intrinsic mechanisms such as down-
egulation of chemotherapy transport proteins and increase in
ulti-drug resistance receptors. However, targeting these cell-
ntrinsic resistance mechanisms has failed to show improved
eukemia-free survival [3,4]. Therefore, increasing focus has been
laced on leukemia cell-extrinsic regulation by the bone marrow
BM) microenvironment.
The BM microenvironment is a complex milieu of hematopoi-
tic and stromal cell types that balances normal hematopoietic
tem and progenitor cell (HSPC) self-renewal and differentia-
ion [5]. A number of soluble and membrane-bound angiocrine
actors produced by sinusoidal ECs and perivascular stromal
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cells have been identiﬁed as crucial signals that maintain quies-
cence and facilitate return to homeostasis following myeloablative
chemotherapy including stem cell factor (SCF), Jagged-1, stromal
cell derived factor 1 (SDF-1), and pleiotrophin [6–8]. Furthermore,
we have demonstrated a developmental relationship between nor-
mal  HSPCs and ECs by showing that adult HSPCs are capable of
hemangioblast activity, generating both blood and blood vessels
[9,10]. Given the close intercellular relationships between normal
HSPCs and ECs in the bone marrow, it is plausible to implicate
ECs in the establishment and progression of malignant HSPCs like
AML.
A number of studies have suggested an intimate role between
AML  and blood vessels. The bone marrow of patients with AML
exhibits increased vascularity and increased angiogenic factors that
portend for worse prognosis independent of other factors such as
cytogenetic abnormalities [11–15]. Recently, we  demonstrated that
AML  cells can integrate within blood vessels, become quiescent,
adopt EC-like features, and re-emerge as CD45+ leukemia cells [16].
Others have demonstrated that AML  cells in proximity to ECs are
more resistant to chemotherapy [17,18]. Together, these results
indict the vascular niche as a major accomplice in AML, worthy
of further study and targeting.
To test our hypothesis that increased bone marrow vascular-
ity protects AML  cells from cytotoxic therapy, we  chose to use the
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ulti-targeted receptor tyrosine kinase inhibitor (RTKI) pazopanib
hat has been shown to block tumor growth and inhibit angiogen-
sis by targeting VEGFRs, PDGFRs, and cKit (SDF-1 receptor) [19].
azopanib is approved for renal cell carcinoma and soft tissue sar-
oma treatment, has a better health-related quality of life and is
ore cost effective than other RTKIs such as sunitinib [20,21].
. Methods
.1. Human AML  cell lines
HL-60 and KG-1 cell lines were purchased from the American Tissue Culture Col-
ection (Manassas, VA) and incubated with 5% CO2 in air at 37 ◦C. HL-60 and KG-1 cell
ines were cultured in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) (Invitrogen)
upplemented with 20% heat-inactivated fetal bovine serum (FBS) (Atlanta Biolog-
cals) and 1% penicillin/streptomycin (Cellgro). Human Umbilical Vein Endothelial
ells (HUVEC) were obtained from ATCC. The cell line was  cultured in Endothelial
rowth Medium-2 (EGM-2) (Lonza) supplemented with EGM-2 Bulletkit (Lonza)
rowth factors. GFP+ HL-60 cells were created using lentiviral transfection.
.2. Therapeutic agents
Pazopanib (Votrient) was provided by GlaxoSmithKline, Inc. For in vitro experi-
ents, pazopanib was  dissolved in a 10 mM stock solution of dimethyl sulfoxide
DMSO) (Sigma–Aldrich). Further dilution to indicated concentrations was done
ith DMSO. Cytarabine (Ara-C) (Sigma–Aldrich) was  dissolved in a 10 mM stock
olution to indicated concentrations with DMSO. For in vivo experiments, pazopanib
as  suspended in 0.5% hydroxypropylmethyl cellulose (HPMC) (Colorcon) and 0.1%
ween-80 in water as a vehicle (pH 1.3–1.5) and given daily by oral gavage. Cytara-
ine  was  given intraperitoneally with 1× Dulbecco’s Phosphate-Buffered Solution
s  a vehicle.
.3. Co-culture studies
For direct contact co-culture studies in a 96-well format, HUVEC cells were
eeded at 2 × 104 cells per well in a 100 uL of culture media and allowed to attach
vernight. HUVEC cells were used in initial experiments as proof-of-principle, as
ell as their reliability and uniformity in cell culture propagation. Only early pas-
age HUVECs were used for co-culture experiments. Subsequently KG-1 cells were
eeded on direct contact at 1 × 105 cells per well in a 100 uL of culture media. Like
ise, for a 24-well format, HUVEC cells were seeded at 5 × 104 cells per well in a 1 mL
f  culture media (EGM-2) and allowed to attach overnight. The next day, EGM-2 was
spirated and the KG-1 cells were seeded on direct contact at 5 × 104 cells per well
n  1 mL of culture media. After treatment with cytarabine (AraC) alone, pazopanib
lone, or a combination of both at indicated time and dose, assays were performed
o determine cell viability or apoptosis.
For transwell co-culture studies HUVEC cells were seeded at 5 × 104 cells per
ell in a 1 mL  of culture media (EGM-2) and allowed to attach overnight. KG-1 cells
ere seeded in transwell inserts the following day at 5 × 104 cells per well in 100 uL
f  culture media. Cell viability was assessed using ﬂow cytometry by staining for PI
nd Annexin V (BD Biosciences).
.4. Cell viability
Cell proliferation was measured using an XTT colorimetric assay (ATCC). Cells
ere seeded on a 96 well plate at 1 × 105 cells per well in 100 uL culture media. After
 24 h incubation with treatment at indicated doses, 50 L of XTT reagent was  added
o  each well and plates were incubated at 37 ◦C for 3 h. Plates were analyzed using
n  Inﬁnite M200 Pro reader (Tecan). Prism (GraphPad) was used to calculate IC50
alues. This same procedure was followed for cells seeded in co-culture as previously
escribed.
The XTT assay was used to quantify cell growth in the drug sensitivity experi-
ents. In brief, an absorbance microplate reader is used to measure the change in
olor that results when a tetrazolium dye is reduced to a soluble, highly pigmented
erivative.
.5. Apoptosis
To measure apoptosis, HL-60 or KG-1 cells were seeded at 2 × 105 cells/mL in
ulture medium and incubated with pazopanib and cytarabine for 48 h at the con-
entrations indicated. Brieﬂy, cells were collected and stained using propidium
odide (PI) and Annexin V-APC (BD Biosciences) according to the manufacturer’s
rotocol. Analysis was performed using a Becton Dickinson FACSCanto II ﬂow
ytometer..6. Human angiogenesis cytokine array
Media supernatants were assayed for the presence of angiogenic cytokines,
fter stimulating the cells with chemotherapy. The assay was performed using thesearch 39 (2015) 984–989 985
Proteome ProﬁlerTM Array from R&D Systems. HUVEC and KG-1 cells were seeded
in  co-culture using a transwell system as previously described. Media was  col-
lected after 48 h of treatment with increasing concentrations of cytarabine. Passage
3  primary human bone marrow endothelial cells (BMECs) were rinsed with 1X
PBS and incubated with (unsupplemented) EBM-2 + GA1000 (antibiotic) and 20 uM
cytarabine for 24 h. Supernatants were collected and then analyzed by cytokine
array. Brieﬂy, the membrane containing immobilized angiogenesis-related antibod-
ies  were blocked with bovine serum albumin for 1 h on a rocking platform at room
temperature. Membranes were then incubated with cell culture supernatants along
with a detection antibody cocktail overnight at 2 ◦C–8 ◦C on a rocking platform. The
membrane was incubated with streptavidin–horseradish peroxidase conjugate fol-
lowed by chemiluminescent detection reagent. The membrane was scanned and
pixel density was presented by quantifying the mean spot densities. Density quan-
tiﬁcation was done using Image J software (NIH).
2.7. cDNA and PCR
RNA isolation from KG-1 and HL-60 cell lines was performed following the
RNeasy Plus Mini Kit protocol (Qiagen) and analyzed with a SmartSpec Plus Spec-
trophotometer (BioRad). Reverse transcription for cDNA was  done following the
High Capacity cDNa Reverse Transcription Kit protocol (Applied Biosciences). PCR
was done using human primers to SCFR, PDGFR- and PDGFR- attained from
Invitrogen Oligos and New England BioLabs reagents. Analysis was done following
agarose gel electrophoresis procedure.
2.8. Western blot
Cells were treated with various concentrations of pazopanib with or without
the  presence of recombinant human SCF or VEGF (R&D Systems). Cell extracts were
isolated using RIPA buffer. For phosphorylation studies, samples were ﬁrst immuno-
precipitated using protein A/G-Agarose (Santa Cruz) in the presence of primary
antibody against human SCFR and then separated on a 4–20% gel. Samples were
then transferred onto a nitrocellulose membrane. The immunoprecipitated sam-
ples were probed with human anti pTYR antibody (Santa Cruz) and human anti
SCF receptor antibody (Santa Cruz). For apoptosis studies whole cell lysates were
separated on a 4–20% gel and subsequently blotted onto a nitrocellulose membrane.
Horseradish peroxidase (HRP)-marked immunoglobulins from Santa Cruz were used
as  secondary antibodies. Antibody binding was detected using chemiluminescence
reagent (ECL Western Blotting Analysis System, Amersham). Furthermore, in trying
to  elucidate a mechanism of action for the drug, protein lysates were immunoblotted
for total and phosphorylated Src (Santa Cruz).
2.9. Mouse xenograft model
All animal studies were performed according to approved protocols from the
University of Florida IACUC. To test the efﬁcacy of pazopanib and cytarabine in
systemic AML  mouse models, human leukemia chimeras were established using
NOD/scid/IL2R−/−(NSG) mice (Jackson Laboratories, Bar Harbor, Maine). 6-week-
old, female NSG mice were inoculated with 1 × 106 GFP-HL-60 or 2 × 106 KG1 cells
via tail vein injection. We allowed for four weeks of engraftment for HL-60 cells
and six weeks engraftment for KG1 cells. The mice were divided into ﬁve groups of
10  mice each: pazopanib, Ara-C, pazopanib + Ara-C, vehicle, and untreated. Treat-
ments were 500 mg/kg of body weight Ara-C (IP) on day 1 and day 2, 100 mg/kg of
body weight pazopanib (oral gavage) daily for 8 days, and 100 uL of HPMC (vehicle
control).
2.10. Tissue analysis
After the last treatment, the liver, kidney, spleen, lungs and femurs were
harvested from all mice for the purpose of investigation. Engraftment was  deter-
mined using ﬂow cytometry staining for human CD45 and HLA (BD Biosciences),
as  well as Viaprobe to determine cell viability. CD45, also known as the leuko-
cyte common antigen, is a highly speciﬁc marker for hematopoietic cells lines.
This marker, together with human speciﬁc anti HLA, was used in order to label
the  human leukemia cells present in the mouse bone marrow. Femurs were sec-
tioned and stained for MECA-32 (BD Biosciences) for the assessment of blood vessel
formation.
2.11. Statistical analysis
Statistical analysis of the data was  performed using Student’s t-test. P values of
<0.05 were considered statistically signiﬁcant.
3. Results
3.1. ECs establish a chemoprotective niche by angiocrine factor
stimulation of AML cells
We initially examined the effect of ECs on AML  cells exposed
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xpresses angiocrine factor receptors (Fig. 1A), we found that KG-
 cells grown in direct contact with ECs exhibited resistance to
ytarabine chemotherapy compared to AML  grown in suspension
Fig. 1B). Treatment of AML  cells in co-culture with HUVECs with
ytarabine for 48 h showed signiﬁcantly decreased AML  cell apo-
tosis compared to cells grown in the absence of an EC layer using
nnexin V and PI staining analysis. To examine the role of direct
ontact between AML  and HUVECs in chemoresistance, we utilized
 co-culture system in which AML  cells were seeded in a transwell
n the presence or absence of an EC feeder layer (Fig. 1C). When
ML  cells that were not directly apposed to the EC feeder layer were
xposed to cytarabine, the chemoprotective effect of the ECs was
reserved indicating that soluble paracrine signals released from
he EC feeder layer are at least partly responsible for the decreased
poptosis observed with cytarabine treatment.
In order to identify angiocrine factors that contribute to the
hemoprotective effect of HUVECs on AML  cells, we analyzed
he media of AML-EC co-cultures after treatment with cytarabine
or soluble EC-derived paracrine factors. We  found signiﬁcantly
ncreased levels of VEGF-A and PDGF-A/B in co-cultures treated
ith cytarabine compared to untreated (data not shown). To
etermine if these cytokines are elicited from primary human
one marrow ECs (BMECs) in response to chemotherapy, we
ultured patient derived BMECs in EGM-2 until conﬂuent. The
rimary BMECs were treated with cytarabine at 20 M for 24 h.
he supernatants were collected and analyzed for PDGF and
EGF-A. BMECs treated with cytarabine secreted 1.6-fold PDGF-
B (p < 0.005) and 40-fold the amount of VEGF (p < 0.05) compared
o untreated BMECs (Fig. 1D). Cytarabine-treated BMECs at this
ime point showed no decrease in viability (Fig. 1E), suggesting
hat the cytokine release was associated with particular angio-
enic/inﬂammatory response. These results are consistent with
rior reports [22–24].
ig. 1. Endothelial cells protect leukemia cells from chemotherapy induced apoptosis in 
xpress  VEGFR1 and VEGFR2. PCR demonstrates HL-60 cells express c-Kit while KG-1 ce
UVECs and treated with varying concentrations of cytarabine. After 48 h of treatment th
G1  AML  cells were more resistant to cytarabine treatment when in co-culture with EC
reated  with varying concentrations of cytarabine. After 48 h of treatment the cells wer
ells  were more resistant to cytarabine treatment when in transwell co-culture with EC
ytarabine chemotherapy, BMECs secreted signiﬁcantly increased VEGF-A (40-fold, p < 0.0
iability  after 24 h treatment with cytarabine chemotherapy at clinically relevant concensearch 39 (2015) 984–989
3.2. Pazopanib treatment results in an additive effect on
apoptosis in combination with cytarabine in vitro
Given the evidence that ECs protect AML  cells from chemother-
apy and the speciﬁc angiogenic cytokines discovered in this
protection (i.e., VEGF-A and PDGF-A/B), we selected pazopanib, a
receptor tyrosine kinase inhibitor (RTKI) with speciﬁcity for VEG-
FRs, PDGFRs, and cKit (SCF receptor), as a potential anti-leukemia
agent in combination with cytarabine. Treatment of HL-60 AML
cells for 48 h with cytarabine alone or pazopanib alone resulted in
a modest decrease in cell viability in vitro; however, when com-
bined, the drugs had an additive effect on viability as measured
by XTT assay (Fig. 2A). This effect of RTK inhibition in the absence
of trophic soluble mediators secreted from ECs is not surprising
given evidence that AML  cells express endothelial-like receptors
(Fig. 1A) and stimulate their own  proliferation with angiocrine
factors via autocrine signaling [25]. Next, we  reasoned that in
the presence of pazopanib RTK inhibition, the chemoprotective
effect afforded by ECs would be abrogated. When AML  cells were
treated with combined therapy (pazopanib + cytarabine), there was
an additive effect on apoptosis (Fig. 2B). Western blot of phospho-
rylated Src kinase, a downstream target of VEGFRs and PDGFRs,
demonstrated a dose dependent response to pazopanib RTK inhi-
bition suggesting a mechanism for direct leukemia cell cytotoxicity
(Fig. 2C).
3.3. Pazopanib treatment in vivo results in decreased AML
engraftment and abrogates cytarabine-induced angiogenesisTo test the effect of pazopanib RTK inhibition in vivo, NSG
mice were injected with 1 × 106 GFP-tagged HL-60 cells and
allowed to engraft. After 4 weeks, mice were treated with
pazopanib, cytarabine, or combination for 8 days. The cohorts were
co-culture. (A) Flow cytometry shows HL-60 cells express VEGFR1 while KG1  cells
lls express c-Kit and PDGFR-a. (B) KG1 cells were seeded in direct co-culture with
e cells were stained with Annexin V and PI, and then analyzed by ﬂow cytometry.
s (p < 0.001). (C) KG1 cells were seeded in transwell co-culture with HUVECs and
e stained with Annexin V and PI, and then analyzed by ﬂow cytometry. KG1 AML
s (p < 0.001). (D) Angiogenic cytokine secretion from primary human BMECs. After
5) and PDGF-A/B (1.6-fold, p < 0.005). RFI = Relative Fluorescence Intensity. (E) BMEC

















































dL. Drusbosky et al. / Leukem
acked and engraftment was determined with ﬂow cytometry.
azopanib, cytarabine, and the combination showed similar levels
f BM engraftment relative to the untreated cohort demonstrat-
ng that pazopanib alone is as effective as conventional cytotoxic
hemotherapy (Fig. 3A). Examination of the bone marrow histology
emonstrated a trend of increased vascularity in mice treated with
ytarabine alone compared to treatment with pazopanib (Fig. 3B
nd C). To conﬁrm reproducibility among cell lines, NSG mice were
njected with 2 × 106 KG1 cells and allowed to engraft for six weeks.
reatment with cytarabine, pazopanib, or a combination reduced
one marrow AML  engraftment comparable to the previous model
Fig. 3D). This angiogenic response to cytarabine is consistent with
he increased angiocrine proﬁle elicited from BMECs treated with
ytarabine in vitro. The increased angiogenic effect of cytarabine
as abrogated with addition of pazopanib (Fig. 3B and C).
. Discussion
Whereas progress in genetics has greatly advanced our under-
tanding of AML as a multi-genetic and oligoclonal disease [26,27],
argeting recurrent genetic mutations and intracellular resistance
echanisms has not improved the 60–80% relapse rate in AML
atients. Therefore, leukemia cell-extrinsic factors in the AML
icroenvironment are gaining greater interest. In this study we
emonstrate that ECs provide protection to AML  cells from cytara-
ine chemotherapy, and that this protection is partly due to
aracrine communication. Our results conﬁrm previous reports
n the broad role of ECs in AML  [28], but also extend our under-
tanding of AML  pathobiology by showing bone marrow relevance
hrough the use of primary BMECs as protective reservoirs. Recently
e demonstrated that AML  cells functionally integrate within
ndovascular linings and exit cell cycle. We  postulated that EC-
ssociated AML  cells would be more resistant to cell cycle active
gents [16]. In this study, we addressed this hypothesis by show-
ng resistance to cytarabine, an S-phase agent, when leukemia cells
ere associated with ECs.
In search of a cell biology explanation, we found that BMECs
ecrete angiogenic/inﬂammatory cytokines, such as VEGF-A and
DGFs, in response to cytarabine. When considering that AML  cells
an also express endothelial-like receptors such as VEGFRs and
DGFRs (Fig. 1 and [29]), the paracrine or angiocrine release from
Cs may  contribute to pathologic protection and promotion of
eukemia. Therefore, we applied an FDA-approved TKI, pazopanib,
ith known inhibition of VEGFRs, PDGFRs, and cKit (SCF recep-
or) and found three outcomes: (1) direct killing of AML  cells, (2)
eversal of EC protection of AML  cells, and (3) abrogation of BM
ngiogenesis.
ig. 2. In vitro ﬂow cytometry apoptosis analysis shows an additive effect of treatment w
emonstrate modest reduction in viability by XTT assay. In combination, the effect is ad
0.05 for all treatment samples, compared to untreated control. (B) In the presence of 
ersists. *p-values <0.05 for all treatment samples, compared to untreated control. (C) W
ose-dependent decrease in phosphorylation with pazopanib exposure.search 39 (2015) 984–989 987
VEGF has been a target of interest for many years in AML
[25,30]. Although monoclonal antibody therapy directed against
VEGF (i.e., bevacizumab) in AML  patients reduces BM VEGF lev-
els, minimal improvements in clinical outcomes are seen [31,32].
Anti-angiogenic TKIs have also been tested as monotherapies in
AML  and have shown mixed responses in early phase clinical tri-
als [33,34]. In the clinical setting of AML  where the disease is
rapidly hyperproliferative, cytoreductive chemotherapy is often
required immediately. From a clinical practical perspective, any
viable microenvironmental targeting strategy for AML, especially
refractory/relapsed disease, will require combination therapy with
a cytoreductive reagent. Therefore, in this study we  tested an anti-
angiogenic RTKI in combination with cytarabine chemotherapy and
demonstrate an enhanced additive effect. Together, these results
support the combination of anti-angiogenic RTKI in combination
with cytarabine for patients with AML. Preliminary results from a
phase I clinical study of sunitinib (RTKI with activity against FLT3,
VEGFRs, PDGFRs, cKit, and others) in combination with standard
AML  induction chemotherapy presented by Fiedler et al. showed
impressive disease response (70% CR/CRi) despite myelosuppres-
sion [35]. Optimizing a combination strategy of targeting the AML
microenvironment plus chemotherapy for AML  will require adjus-
ting the dose of cytoreductive chemotherapy, intentional selection
of patients with AML  myeloblasts expressing relevant EC-like
receptors, and/or rationally designing a timed-sequential therapy
based on angiogenic cytokine release as Karp et al. previously
piloted [31].
When considering our study, several considerations should be
made. First, our initial experiments utilized HUVECs, which may
differ from ECs that interact with leukemia cells. To address this,
we harvested primary BM specimens from patients, established
BMECs, and used these to conﬁrm EC-AML protection. In follow-up
experiments, we  will test whether there are differences between
healthy volunteer BMECs and leukemia BM-derived BMECs. It may
also be interesting to test EC–AML interactions in serum free con-
ditions, such as with adenovirus E4+ ECs [6]. Second, we  used AML
cell lines rather than primary AML  specimens. The main reason
for cell line usage was  because the focus of our experiments was
on targeting known RTKs, rather than discovering new receptors
in AML. Prior investigators have done an excellent job demon-
strating EC-like expression on primary AML  myeloblasts, and we
found no cause to repeat these experiments [30,36]. Finally, the
xenograft model showed signiﬁcant BM regression of leukemia
in the RTKI cohorts, but no improved BM regression when com-
bining RTKI with cytarabine. Reasons for this may include the
dosing and schedule of the treatment agents. We  approximated
clinically relevant dosing; however, drug dose and schedule are
ith pazopanib and cytarabine. (A) KG-1 cells exposed to pazopanib and cytarabine
ditive, signiﬁcantly decreasing viability of AML  cells relative to controls. *p-values
an EC feeder layer, the addictive effect of pazopanib and cytarabine on AML  cells
estern blot of phosphorylated SRC, a downstream target of RTK signaling, shows a
988 L. Drusbosky et al. / Leukemia Research 39 (2015) 984–989
Fig. 3. Pazopanib treatment decreases engraftment equivalent to cytarabine and disrupts microvessel formation. (A) Pazopanib and cytarabine decreased the level of HL-
60  engraftment equally. The decrease in engraftment for all treatment groups was  determined by ﬂow cytometry analysis. HL-60 engraftment for untreated mice was
approximately 34%. HL-60 engraftment for treated mice ranged 12–18%. *p-values <0.05 for all treatment samples compared to untreated control. (B) Pazopanib treatment
leads  to a reduction in the number of blood microvessels within leukemic cores compared to other treatment groups. Quantiﬁcation of microvessels based on MECA-32+.
Values  represent mean ± SEM. p < .05. (C) Representative bone marrow micrographs showing microvessel density (MECA-32 endothelial stain, red) and nuclear staining
(DAPI,  blue) of mouse femurs after transplant with human AML  cells (HL-60) and treatment with pazopanib and cytarabine. Untreated animals with robust AML  engraftment
showed high microvessel density in the bone marrow. Pazopanib alone markedly decreased microvessel density in the bone marrow. Cytarabine also decreased microvessel
density. The combination of pazopanib and cytarabine also caused marked reduction in blood vessels within bone marrow. (D) Pazopanib and cytarabine decreased levels of
bone  marrow KG1 engraftment equally. The decrease in engraftment for all treatment groups was  determined by ﬂow cytometry analysis. KG1 engraftment for untreated
mice  ranged 59–80%. KG1 engraftment for treated mice ranged 33–78%. **p-values <0.005, *p-value <0.05 for all treatment samples compared to untreated control. (For











































[36] S. Dias, et al., Vascular endothelial growth factor (VEGF)-C signaling throughL. Drusbosky et al. / Leukem
ifﬁcult to establish and extrapolate in mouse models, especially
SG xenografts [37]. At a minimum, our results show strong proof-
f-principle that pazopanib RTK inhibition has in vivo activity in
ML. Moreover, abrogation of BM hypervascularity may  show its
reatest beneﬁt in terms of time to relapse, which can take sev-
ral months to years in human patients. By reducing the number
f vascular niches that serve as protective reservoirs of disease,
nti-angiogenic RTKIs may  winnow niches for minimal residual
isease.
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